The 20 Best Dementia Doctors Near Me in Ann Arbor, MI

Kenneth Langa is a primary care provider, practicing in Internal Medicine in Ann Arbor, Michigan. Dr. Langa is rated as an Elite provider by MediFind in the treatment of Dementia. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Dementia, Developmental Dysphasia Familial, Memory Loss, and Stroke.

Kirk Frey is a Neurologist and a Nuclear Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Frey is rated as a Distinguished provider by MediFind in the treatment of Dementia. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Neuroendocrine Tumor, Osteopenia, and Hormone Replacement Therapy (HRT).

Henry L. Paulson, M.D., Ph.D., is the Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan. Dr. Paulson joined the U-M faculty in 2007, and he currently directs the Michigan Alzheimer’s Disease Center (MADC) and co-direct the U-M Protein Folding Diseases Initiative.Dr. Paulson received his medical degree and doctorate in Cell Biology from Yale University in 1990. He then completed a neurology residency and neurogenetics/movement disorders fellowships at the University of Pennsylvania. In 1997, he joined the Neurology faculty at the University of Iowa, where he remained until 2007.Dr. Paulson's research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on polyglutamine diseases, Alzheimer's disease and frontotemporal dementia. In 1997, his lab described abnormal protein aggregates in the polyglutamine diseases, which now are recognized as a pathological hallmark in this important class of inherited diseases. Using test tube, cell-based and animal models, he has contributed to advances in the understanding of various neurodegenerative diseases. His lab also has helped pioneer the use of gene silencing methods as potential therapy for the many neurological disorders caused by toxic mutant genes.Nationally, Dr. Paulson has directed popular courses at the American Academy of Neurology meetings, serves on the scientific advisory boards of numerous disease-related national organizations, and is past Chair of the Board of Scientific Counselors at the National Institute for Neurological Disorders and Stroke at the National Institutes of Health.Among his awards, Dr. Paulson is an Ellison Medical Foundation New Scholar in Aging, a semifinalist for the W.M. Keck Foundation Young Scholars in Medical Research, and a recipient of the Paul Beeson Physician Faculty Scholar in Aging Award from the American Federation for Aging Research. Dr. Paulson is rated as a Distinguished provider by MediFind in the treatment of Dementia. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 3, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology.

Roger L. Albin, M.D. (Residency 1986), is a professor of neurology, associate chair for research and co-director of the Movement Disorders Clinic in the Department of Neurology in the University of Michigan Medical School. In addition, he serves as chief of neuroscience research at the VA Ann Arbor Healthcare System Geriatric Research Education and Clinical Center.Dr. Albin joined the U-M faculty in 1988 as an instructor in the Department of Neurology. He was promoted to assistant professor in 1989; associate professor in 1994; and achieved his current rank of full professor in 2000.After completing his undergraduate degree at Oberlin College in Ohio, Dr. Albin earned his medical degree from the University of Pittsburgh School of Medicine in 1982, and completed his residency at the University of Michigan in 1986. He also completed a movement disorders fellowship in 1988 under Drs. Anne Young and John Penney.His clinical and research interests include the underlying neurobiologic causes of the clinical features of movement disorders, basal ganglia structure and function, Parkinson's disease, Tourette syndrome, dementias, dystonias and Huntington's disease. His laboratory is pursuing work on basic mechanisms of neurodegeneration in Huntington disease using mouse genetic models. Dr. Albin also has participated in neuroprotective clinical trials for both Huntington's disease and Parkinson's disease.The present focus of Dr. Albin's group is uncovering the basis for non-motor (sleep disorders, depression, dementia, autonomic dysfunction) problems in Parkinson's disease. He is very interested in applying positron emission tomography (PET) imaging methods to improve diagnosis of dementing disorders like Alzheimer's disease. The hope is that understanding how specific brain alterations cause specific clinical features will lead to improved treatments.Dr. Albin currently serves as a site investigator for the National Institutes of Health (NIH) Exploratory Trials in Parkinson disease (NET-PD) initiative. His work is supported by grants from the NIH, the Michael J. Fox Foundation and the High Q Foundation.A member of the American Academy of Neurology, the American Association for the Advancement of Science, the American Neurologic Association, and the Society for Neuroscience, Dr. Albin currently serves on the editorial boards of Experimental Neurology, Neurology and Neurobiology of Disease. Dr. Albin is rated as a Distinguished provider by MediFind in the treatment of Dementia. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Movement Disorders, Parkinson's Disease, Huntington Disease, Dementia, and Deep Brain Stimulation. Dr. Albin is board certified in Neurology.

Judith Heidebrink is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Heidebrink is rated as a Distinguished provider by MediFind in the treatment of Dementia. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Alzheimer's Disease, Cerebellar Degeneration, Lewy Body Dementia (LBD), and Dementia.

Sami Barmada, M.D., Ph.D. is an assistant professor of neurology at the University of Michigan Medical School. His clinical interests center around patients with dementia and motor neuron disease, and he sees patients at the Cognitive Disorders Clinic in the University of Michigan’s East Ann Arbor location.His research focuses on the pathologic overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and how we can take advantage of the convergence to identify new and effective therapies for these devastating disorders.After graduating from the University of Pittsburgh, Pennsylvania, in 1998 with a major in Molecular Biology, Biochemistry, and a focus in Conceptual Foundations of Medicine, Dr. Barmada went on to the Medical Scientist Training Program at Washington University in St. Louis School of Medicine. For his graduate work, he constructed a transgenic mouse model of Creutzfeldt-Jacob disease with Dr. David Harris, and used these animals to track the deposition of misfolded prion protein within the nervous system of infected animals. For this work, Dr. Barmada earned earned the Poletsky Award from the Alzheimer’s Disease Research Center in St. Louis, Missouri, and was elected as a Olin Medical Scientist Fellow at Washington University School of Medicine.Dr. Barmada received his M.D. and Ph.D. in 2006, and completed an Internal Medicine internship at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, before moving to the University of California, San Francisco (UCSF), Medical Center for his residency in Neurology. Dr. Barmada served one year as Chief Resident in the Department of Neurology, focusing on resident education. He was also a house-staff nominee to the Alpha-Omega-Alpha honor society. During his residency, Dr. Barmada became involved in research with Dr. Steve Finkbeiner of the Gladstone Institutes, a pioneer in neuronal models of neurodegenerative disease and novel technologies to study these models. Dr. Barmada finished his residency in 2010 and spent one year working with Dr. Finkbeiner as a research fellow, before becoming a Staff Scientist at the Gladstone Institutes and a Clinical Instructor at UCSF. In 2013, Dr. Barmada became an Assistant Professor of Neurology at the University of Michigan, where he divides his time between the Cognitive Disorders Clinic and the laboratory. Dr. Barmada is rated as a Distinguished provider by MediFind in the treatment of Dementia. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Frontotemporal Dementia, and Dementia. Dr. Barmada is board certified in Neurology.

Dr. Maust earned his medical degree from Johns Hopkins University. He completed his psychiatry residency and geriatric psychiatry fellowship at the University of Pennsylvania, with further training in health services research at the University of Michigan. He is an assistant professor in the Department of Psychiatry and a research scientist in the Center for Clinical Management Research of the VA Ann Arbor Healthcare System. Dr. Maust is rated as a Distinguished provider by MediFind in the treatment of Dementia. He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses Dementia and Alzheimer's Disease. Dr. Maust is board certified in Psychiatry and Geriatric Psychiatry.

Dr. MacDonald grew up in St. Ignace, a small town in Michigan’s Upper Peninsula. He attended medical school at Michigan State University’s College of Human Medicine. From there, he completed his neurology residency and then a fellowship in Behavioral Neurology at the Cleveland Clinic.Dr. MacDonald’s primary interests are related to the diagnosis and management of different neurodegenerative diseases of the brain such as Alzheimer’s disease, Lewy body disease, vascular dementia, and frontotemporal dementia. In addition to his clinical activities, Dr. MacDonald has also participated in several clinical trials assessing the safety and efficacy of drugs designed to slow the progression of certain neurodegenerative disorders. Dr. Macdonald is rated as a Distinguished provider by MediFind in the treatment of Dementia. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Cerebellar Degeneration, Dementia, Charles Bonnet Syndrome, Primary Progressive Aphasia, and Hip Replacement. Dr. Macdonald is board certified in Neurology.

Rachel Denny is a primary care provider, practicing in Internal Medicine and Geriatrics in Ann Arbor, Michigan. Dr. Denny is rated as an Experienced provider by MediFind in the treatment of Dementia. Her clinical expertise encompasses Delirium, Lewy Body Dementia (LBD), Neuronal Intranuclear Inclusion Disease (NIID), and Heart Failure. Dr. Denny is board certified in Family Medicine and Geriatric Medicine.

Nicolaas Bohnen is a Neurologist and a Nuclear Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Bohnen is rated as an Advanced provider by MediFind in the treatment of Dementia. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Osteopenia, Melorheostosis, and Deep Brain Stimulation.

Dr. Feldman is the director of the NeuroNetwork for Emerging Therapies at Michigan Medicine and the ALS Center of Excellence at Michigan Medicine. The latter includes the Pranger ALS Clinic, one of the top multidisciplinary clinics caring for those suffering from amyotrophic lateral sclerosis (ALS). She serves as the University of Michigan James W. Albers Distinguished University Professor and the Russell N. DeJong Professor of Neurology at Michigan Medicine. Dr. Feldman is one of the world’s leading authorities on neurodegenerative disease.Dr. Feldman is a compassionate and dedicated physician who cares deeply about her patients. She has been recognized for her clinical excellence by numerous organizations and is annually named as one of the “Best Doctors in America.” Her forward-thinking, collaborative, multidisciplinary approach has transformed how neurodegenerative diseases are diagnosed, treated, and prevented.Dr. Feldman has made significant contributions to biomedical research and clinical care in many critical areas of neurodegenerative disease. She has authored over 530 peer-reviewed publications, 74 book chapters, and 5 books on the pathology, diagnosis, and treatment of neurological diseases. Dr. Feldman has been continuously funded by the NIH since 1989 and is currently the principal or co-investigator of numerous clinical trials and grants. She has received numerous awards and honors throughout her remarkable career, including the University of Michigan’s Early Distinguished Career Award, the Distinguished Faculty Achievement Award, and the Distinguished Alumnus Achievement Award. She was also the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. In 2022, Dr. Feldman was awarded the University of Michigan Distinguished Professorship, the highest faculty honor at University of Michigan.Dr. Feldman is actively committed to and involved in professional service. She served as President of the Peripheral Nerve Society from 2007-2009 and President of the American Neurological Association (ANA) from 2011-2013. Dr. Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. Dr. Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology, Nature Reviews Neurology, JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry. Dr. Feldman is rated as an Advanced provider by MediFind in the treatment of Dementia. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Peripheral Neuropathy, Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Autonomic Neuropathy. Dr. Feldman is board certified in Neurology and Electrodiagnostic Medicine.

Navid Seraji-Bozorgzad, MD, is an associate professor of neurology in the University of Michigan Medical School.Dr. Seraji-Bozorgzad began work in the area of medical imaging in 1990 as a research assistant during his undergraduate studies at the University of Michigan. He became familiar and developed a fundamental understanding of image acquisition and processing from his work on solid-state imaging arrays. After undergraduate work, he worked in the private sector as a software engineer, designing databases for various companies, including Ford Motor Company, and Liberty Mutual Insurance. The work provided him with experience in data-mining and manipulation of large datasets.His passion for medicine eventually led him to medical school. During the application process he worked in the Department of Psychiatry and Behavioral Neurosciences, and eventually enrolled in graduate school in neuroscience. While in the Department of Psychiatry, he participated in the use of various MR imaging techniques, including magnetic resonance spectroscopy and functional MRI for diagnosis and disease progression in mood disorders, including bipolar disorder. It was during his graduate studies that he developed an interest in the field of neurodegeneration, regeneration and neuroprotection.Dr. Seraji-Bozorgzad's research interest is primarily with non-invasive methods of monitoring disease progression in neurodegenerative disorders, with the ultimate goal of developing a tool set to monitor the efficacy of therapies early on in neurodegenerative disorders.His bibliography includes numerous peer-reviewed jornals and publications, abstracts and other media. Dr. Seraji is rated as an Advanced provider by MediFind in the treatment of Dementia. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Cerebellar Degeneration, Dementia, Vascular Dementia, and Alzheimer's Disease.

Dr. Stoltz received her undergraduate and medical school degrees at the University of Michigan. Following her Internal Medicine residency, she completed fellowship training in Medical Oncology and Geriatric Medicine. She is board-certified in Geriatric Medicine and Hospice and Palliative Medicine. Dr. Stoltz has a clinical interest in palliative care/hospice care and is the Medical Director of Elara Caring Hospice in Brighton and Lansing, Michigan. Dr. Stoltz is rated as an Advanced provider by MediFind in the treatment of Dementia. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Postmenopausal Osteoporosis, Dementia, Vitamin D Deficiency, and Osteoporosis.

Dr. Bynum is the Margaret Terpenning Professor of Medicine in the Division of Geriatric Medicine, Research Professor in the Institute of Gerontology, Geriatric Center Associate Director for Health Policy and Research, and a member of the Institute for Healthcare Policy and Innovation. She received her medical and public health degrees from Johns Hopkins, did her residency and chief residency at Dartmouth, and completed specialty training in Geriatric Medicine at Johns Hopkins. At University of Michigan, Dr. Bynum has a robust NIH-funded research program including a NIA Center for Aging and Demography of Alzheimer’s Disease, called the Center to Accelerate Population Research in Alzheimers (CAPRA), for which she is the principal investigator. Dr. Bynum became Vice Chair for Faculty Affairs for the Department of Internal Medicine in 2021. Dr. Bynum is rated as an Advanced provider by MediFind in the treatment of Dementia. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Dementia, Alzheimer's Disease, Urinary Incontinence, and COVID-19.

Dr. Gerlach is a Geriatric Psychiatrist and Assistant Professor in the Department of Psychiatry. Her research is focused on understanding trends and appropriate use of psychotropic medications among older adults including evaluating how psychotropic medications are utilized in end-of-life care. She has used national survey and administrative claims data to evaluate the growth of central nervous system (CNS) medication polypharmacy use among older adults and to understand how health systems respond to warnings (e.g., from the U.S. FDA) for psychotropic medications. Her work aims to inform safe and rationale psychotropic medication prescribing among older adults with mental health and cognitive disorders--including understanding how to best target appropriate treatment to patients that would benefit from treatment the most. Dr. Gerlach is rated as an Advanced provider by MediFind in the treatment of Dementia. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Dementia, Seasonal Affective Disorder (SAD), Major Depression, and Alzheimer's Disease.

Peter K. Todd, M.D., Ph.D., is an assistant professor in the Department of Neurology in the University of Michigan Medical School.Dr. Todd earned his Bachelor of Science degree in 1994 from the University of California, San Diego. He then entered the Medical Science Training Program at the University of Wisconsin at Madison, where he completed his doctorate in 2002 and medical degree in 2004. His Ph.D research focused on synaptic defects in Fragile X Syndrome, a common inherited cause of cognitive impairment in children.He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While there, he did research on the role of the ubiquitin proteasome system and autophagy in Spinal and Bulbar Muscular Atrophy, a polyglutamine disorder, and Fragile X Tremor Ataxia Syndrome (FXTAS). He came to the U-M in 2008 for a clinical and research fellowship in movement disorders and neurogenetics.Todd joined the U-M faculty in 2010 as an assistant professor in movement disorders and neurogenetics, working in the laboratory of Henry L. Paulson, M.D., Ph.D., in the Center for Neurodegenerative Research.His current research is focused on the mechanisms underlying RNA-mediated neurodegeneration in FXTAS and myotonic dystrophy, and how these mechanisms may overlap and inform our understanding of other neurodegenerative disorders. He also sees patients with movement disorders and inherited neurological disease.Dr. Todd has received several academic awards, including a Howard Hughes Undergraduate Research Fellowship, the Francis M. Forester Prize for promise as an academic neurologist, the Samuel Ziritzky Prize for most outstanding research by a neurology resident at Penn and prizes for excellence in research at the International Conference on Unstable Microsatellites in Human Disease, and the U-M neuroscience day. Most recently, Dr Todd received the S. Weir Mitchell Alliance award from the American Academy of Neurology which each year recognizes one early investigator physician scientist who has made important contributions to basic science in neurological disorders.A member of the American Medical Association and the American Academy of Neurology, he has served as an ad-hoc reviewer for the Journal of Biological Chemistry, Neurology, Proceedings of the National Academy of Sciences, Neuron, Science and Human Molecular Genetics.His bibliography includes several peer-reviewed papers, editorials, book reviews and chapters, abstracts and online. Dr. Todd is rated as an Advanced provider by MediFind in the treatment of Dementia. He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Fragile X Syndrome, Fragile XE Syndrome, Hereditary Ataxia, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Dr. Todd is board certified in Neurology.

Darin B. Zahuranec, M.D. (Residency 2005), is a professor of neurology in the University of Michigan Medical School. He joined the U-M faculty in 2005 as a clinical lecturer in the Department of Neurology, and was promoted to professor of neurology in 2007.Dr. Zahuranec received his bachelor's degree, summa cum laude, from Case Western Reserve University in Cleveland, Ohio, in 1997, and earned his medical degree from Case Western Reserve in 2001. He completed an internship at University Hospitals of Cleveland; residency in the Department of Neurology at the U-M, where he served as chief resident in 2004-05; and a fellowship in stroke and cerebrovascular disease here.In addition to his U-M appointments, Dr. Zahuranec also has served as a staff physician in the Department of Neurology at the VA Ann Arbor Healthcare System and a research staff physician in emergency medicine at Saint Joseph Mercy Hospital in Ann Arbor.His current research activities include, Pilot Study of Gated Cardiac Magnetic Resonance Imaging for Detection of Embolic Source after Ischemic Stroke, Brain Atrophy in Intracerebral Hemorrhage Patients, Brain Attack Surveillance in Corpus Christi (BASIC), Carotid Occlusion Surgery Study (COSS), and Randomized Evaluation of Recurrent Stroke Comparing Patent Foramen Ovale Closure to Established Current Standard of Care Treatment (RESPECT).Dr. Zahuranec has served as an ad hoc reviewer for Neurology, the New England Journal of Medicine and the Journal of Neuroophthalmology, and currently reviews for Stroke. He is a member of the Stroke Council of the American Heart Association, the American Academy of Neurology and the American Medical Association.His bibliography includes numerous peer-reviewed publications, book chapters, abstracts and clinical papers. Dr. Zahuranec is rated as an Experienced provider by MediFind in the treatment of Dementia. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Stroke, Transient Ischemic Attack (TIA), Moyamoya Disease, Thrombectomy, and Stent Placement. Dr. Zahuranec is board certified in Vascular Neurology and Neurology.

Michael M. Wang, M.D. Ph.D., is an assistant professor of neurology and director of molecular stroke research in the Department of Neurology at the University of Michigan. He also is an assistant professor of molecular and integrative physiology at the U-M and a physician in neurology at the VA Ann Arbor Healthcare System.Dr. Wang's research includes laboratory investigations into the molecular basis of stroke and the interaction between stroke, circadian rhythms and disordered sleep. A major interest of the lab is investigating the causes and treatment of CADASIL (Cerebral Autosomal Dominant Arteriopathy Subcortical Infarcts and Leukoencephalopathy), a devastating inherited cause of stroke and vascular dementia. His other interests include studies of the functions of endogenous hormones (estrogen) and differentiation factors on neurons.He received his bachelor's degree, summa cum laude, from Harvard University and earned his medical degree and doctorate in molecular biology and genetics from Johns Hopkins University (JHU) in 1994. In 1998, he completed his neurology residency at JHU; in 2000, he completed a stroke research fellowship with Drs. Richard Traystman and Patricia Hurn. Dr. Wang spent three years on the neurology faculty at JHU before joining the U-M faculty in 2003. During his time at JHU, he also served as a staff neurologist at the Johns Hopkins Hospital and the Johns Hopkins Bayview Medical Center, both in Baltimore, Maryland.Dr. Wang was elected to Phi Beta Kappa during his junior year at Harvard and to Alpha Omega Alpha at JHU. While a fellow, he was awarded funding from the National Stroke Association and the American Heart Association, and also received a Burroughs Wellcome Career Award in Biomedical Sciences. His research has been supported by the National Institutes of Health (NIH) since 2001.He has published his scientific work in Nature, Journal of Neuroscience and Stroke, and has served as a member of national grant review committees of the NIH and the American Heart Association. His bibliography includes more than 20 peer-reviewed publications, seven book chapters, and numerous abstracts and clinical papers. He also is an ad hoc reviewer for the Journal of Cerebral Blood Flow and Metabolism, American Journal of Physiology, Stroke, and Neurology, among others.At the U-M, Dr. Wang is involved in medical student pre-clinical education, resident education and clinical studies conducted by the U-M Brain Injury Group. He is a member of the Stroke Council of the American Heart Association and a member of the Society of Neuroscience. Dr. Wang is rated as an Experienced provider by MediFind in the treatment of Dementia. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, Vascular Dementia, Stroke, Stent Placement, and Transmyocardial Revascularization. Dr. Wang is board certified in Vascular Neurology and Neurology.

Dawn Kleindorfer is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Kleindorfer is rated as an Experienced provider by MediFind in the treatment of Dementia. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Stroke, Transient Ischemic Attack (TIA), Spasticity, Embolectomy, and Thrombectomy. Dr. Kleindorfer is board certified in Neurology and Vascular Neurology.

Mellanie V. Springer, M.D., M.S. is an assistant professor of neurology at the University of Michigan Medical School. Dr. Springer specializes in vascular neurology. Her research interests are in racial and ethnic disparities in stroke treatment/outcomes and social determinants of health.Dr. Springer received her bachelor’s degree from the University of Toronto. She completed a master’s degree in cognitive neuroscience at the University of Toronto. She earned her medical degree from the Albert Einstein College of Medicine in 2009. Dr. Springer then completed her medicine internship, neurology residency, and vascular neurology training at Montefiore Medical Center in the Bronx, NY. She joined the faculty of Montefiore Medical Center as an assistant professor of neurology in 2014. As a junior faculty member at Montefiore, she completed a master’s degree in clinical research methods. Dr. Springer joined the faculty of the University of Michigan Medical School in 2018.Dr. Springer has peer-reviewed publications on cognition and aging, subarachnoid hemorrhage, and racial and ethnic disparities in stroke treatment. Dr. Springer is rated as an Experienced provider by MediFind in the treatment of Dementia. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Stroke, Transient Ischemic Attack (TIA), Moyamoya Disease, Transmyocardial Revascularization, and Stent Placement. Dr. Springer is board certified in Neurology and Vascular Neurology.